Novavax short on options after vaccine fails trial : biopharmadive

as mentioned in biopharmadive

Novavax short on options after vaccine fails trial

Novavax short on options after vaccine fails trial

Dive Brief:Novavax, a Maryland-based vaccines company, suffered a major setback on Thursday, announcing results from a large Phase 3 study which showed its lead vaccine candidate was no more effective than a placebo.Shares in Novavax collapsed on the news, dropping by over 80% in early Friday trading.Novavax, which said it was "surprised and disappointed" by the results, had envisioned peak annual revenues for the vaccine reaching as high as between $6 and $8 billion, according to a regulatory filing released last month.


coupled with marketwatch

Novavax shares plummet more than 80% after vaccine trial fails

Novavax shares plummet more than 80% after vaccine trial fails

Novavax Inc. NVAX, -84.53% shares plummeted in the extended session Thursday after the vaccine company said one of its lung infection vaccines did not meet endpoints in a late-stage clinical trial.Novavax shares plunged 84% to $1.30 on volume of more than 16 million shares.The company said its study in older adults for a vaccine against respiratory syncytial virus, which can cause bronchitis and pneumonia, did not meet primary or secondary clinical trial goals.


coupled with foxnews

Novavax vaccine for respiratory disease fails in late stage trial

Novavax vaccine for respiratory disease fails in late stage trial

Novavax Inc said on Thursday that its experimental vaccine for a serious infectious respiratory disease failed at the final stage of human testing, sending its stock plunging more than 80 percent.The drug failed to meet the main or secondary efficacy goals of a Phase III trial of nearly 12,000 older adults, the company said in a news release.The trial was intended to show that the Novavax vaccine could prevent moderate to severe respiratory syncytial virus, commonly known as RSV.


not to mention fiercepharma

Novavax shares wiped after PhIII RSV vaccine failure

Novavax shares wiped after PhIII RSV vaccine failure

Triggering a huge after-hours selloff, Gaithersburg, MD-based Novavax reported Thursday that its RSV vaccine candidate flunked a big Phase III trial.The failure of the vaccine, which some analysts have pegged to reach more than $800 million by 2022 sales, wiped 85% away from the biotech's former $2 billion-plus market cap.In a Phase III study of 11,856 people 60 and older, Novavax's ($NVAX) F-protein recombinant nanoparticle RSV vaccine missed its primary and secondary objectives while failing to demonstrate efficacy.